Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.

Gossamer Bio, Inc.

Gossamer Bio, Inc. ($GOSS) and two of its executives have asked a federal court to dismiss a securities fraud lawsuit brought by investors followin...

Gossamer Bio Defendants Move to Dismiss Securities Lawsuit Over PROSERA Trial Disclosures

The latest announcement is out from Gossamer Bio ( ($GOSS) ). On September 10, 2026, Gossamer Bio implemented a 1-for-80 reverse stock split of its...

Gossamer Bio Executes Reverse Stock Split and Share Reduction

Gossamer Bio ( ($GOSS) ) just unveiled an announcement. On July 14, 2026, Gossamer Bio stockholders approved a range of potential reverse stock spl...

Gossamer Bio Announces 1-for-80 Reverse Stock Split

Gossamer Bio ( ($GOSS) ) has provided an announcement. On September 3, 2026, Gossamer Bio, Inc.’s board of directors approved an amendment and rest...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	GOSS	$11.24	+2.74%	183.39K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	GOSS	$11.24	+2.7%	183.39K
3
4
5
6

GOSS

Get Gossamer Bio, Inc. Data in Excel

Get Gossamer Bio, Inc. Data in Excel